(CercleFinance.com) – Valneva announces that it has begun submitting the marketing authorization application to the Food and Drug Administration (FDA) for its single-shot vaccine candidate against chikungunya in the elderly 18 and over.
This marketing authorization application follows the final Phase 3 data announced in March 20221 and the final results of the clinical batch homogeneity trial announced in May 20222.
For Juan Carlos Jaramillo, Chief Medical Officer of Valneva, this is an “extremely important” step in the VLA1553 program. “We are very proud to be the first company in the world to have started submitting a marketing authorization application for a chikungunya vaccine candidate,” he added.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
